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In	our	study,	we	investigated	transient	global	cerebral	ischemia	(TGCI)	-induced	changes	of	
spatial	memory	and	motor	activity	together	with	apoptotic,	oxidant,	and	NO/NOS	signaling	
parameters	in	rats	and	the	effects	of	treatment	of	the	animals	with	ghrelin.	The	TGCI-induced	
deficiencies	of	 spatial	memory	and	motor	 activity	 in	 the	Y-maze	and	open	 field	 tests	were	
attenuated	 by	 ghrelin	 treatment.	 Furthermore,	 ghrelin	 administration	 lowered	 the	 levels	 of	
caspase-3	and	iNOS	elevated	by	TGCI	in	the	hippocampus.	Thus,	we	conclude	that	ghrelin	
exerts	the	neuroprotective	action	against	hippocampal	TGCI	injury	via	influencing	apoptotic,	
oxidant,	and/or	NO/NOS	pathways.	If	underlying	mechanisms	of	the	action	of	this	agent	will	
be	fully	clarified,	ghrelin	might	be	a	candidate	drug	for	treatment	of	TGCI-induced	memory	
impairments.
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INTRODUCTION
Transient	 global	 cerebral	 ischemia	 (TGCI),	 usually	
stemming	 from	 a	 severe	 arrhythmia,	 cardiac	 arrest,	
or	 hemorrhagic	 shock,	 is	 a	 leading	 cause	 of	 death	
and	 adult	 disability	 in	 industrialized	 countries,	 and	
the	 respective	 treatment	 options	 are	 limited	 [1].	
Even	 though	 several	 agents	 have	 been	 found	 to	 be	
neuroprotective	 in	 animal	 models,	 most	 of	 them	
have	 failed	 to	 be	 transferred	 from	 the	 laboratory	 to	
the	clinics	 [2].	Thus,	 there	 is	a	huge	medical	need	 to	
develop	novel	therapies	for	TGCI.
Neurophysiological 	 dysfunct ions, 	 including	
learning	and	memory	disabilities,	are	major	outcomes	
of	 TGCI,	 mediated	 through	 delayed	 neuronal	 death	
(DND)	 starting	 2-3	 days	 after	 reperfusion	 mostly	
in	 the	 cerebral	 cortex	 and	 hippocampus	 [1].	 The	
latter	 is	 the	 brain	 structure	 greatly	 vulnerable	 to	
neurodegenerative	 effects	 of	 TGCI	 in	 humans	 [3-
5]	 and	animals	 [6].	Hence,	behavioral	 and	cognitive	
disturbances,	 particularly	 within	 the	 learning	 and	
memory	 domains,	 are	 the	 most	 apparent	 symptoms	
of	 TGCI,	 and	 loss	 of	 spatial	 learning	 and	 memory	
abilities	are	the	parameters	usually	described	in	rodent	
models	of	TGCI	[7].	
Delayed	 neuronal	 death	 is	 suggested	 to	 involve	
apoptosis,	 the	 programmed	 cell	 death	 	 essential	 for	
eliminating damaged or aged cells and maintaining 
tissue	 integrity	 [8].	 The	 specific	 morphological	
changes	associated	with	apoptosis	are	cell	shrinkage,	
c h roma t i n 	 conden s a t i on , 	 i n t e r nuc l eo soma l	
deoxyribonucleic	 acid	 (DNA)	 fragmentation,	 and	
formation	 of	 apoptotic	 bodies	 [9].	 The	 majority	
of	 morphological	 and	 biochemical	 changes	 stem	
from	various	enzymatic	 reactions	most	of	which	are	
catalyzed	by	caspases	playing	essential	 roles	during	
apoptotic	 cell	 death	 [10].	 There	 are	 two	 types	 of	
caspases:	 initiator	 caspases	 (caspases	 8,	 10,	 9,	 and	
2)	 and	 effector	 caspases	 (caspases	 3,	 7,	 and	 6);	 the	
latter	are	activated	by	 initiator	ones	 [11].	Among	all	
members	of	the	caspase	family,	caspase-3	is	the	most	
abundant	in	the	brain,	and	its	activation	is	considerably	
implicated	in	ischemic	cell	death	[12].	
Oxidative	 stress,	 stemming	 from	distortion	 of	 the	
equilibrium	 between	 production	 and	 scavenging	 of	
free	radicals,	is	one	of	the	most	important	pathological	
mechanisms	 leading	 to	 DND	 following	 TGCI	 [13].	
Beside	 oxidative	 stress,	 nitrosative	 stress	 is	 another	
pathological	 mechanism	 significantly	 contributing	
to	 DND	 induced	 by	 excessive	 nitric	 oxide	 (NO)	
production	 through nitric	 oxide	 synthases	 (NOSs)	
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enzymes	 [14].	 The	 role	 of	 NO	 in	 pathogenesis	 of	
ischemic	brain	damage	is	controversial.	Some	evidence	
has	been	accumulated	 that	NO	plays	both	neurotoxic	
and	 neuroprotective	 roles	 during	 the	 process	 of	
cerebral	ischemia	and	reperfusion	[15,	16].	Moreover,	
modulation	of	different	NOSs,	such	as	neuronal	NOS	
(nNOS),	inducible	NOS	(iNOS),	and	endothelial	NOS	
(eNOS),	 have	 been	 shown	 to	 produce	 a	 variety	 of	
outcomes	in	ischemic	brain	injury	[17].	Neuronal	NOS	
and	especially	iNOS	activities	have	been	proposed	to	
be	detrimental	 to	 the	 ischemic	brain	 [18-20].	Hence,	
agents	 preventing	 iNOS	 overexpression,	 such	 as	
ghrelin,	might	be	potential	therapeutic	means	in	TGCI	
[21].
Ghrelin	 is	a	28-amino	acid	peptide	esterified	with	
octanoic	acid	on	serine	3.	 It	 is	mainly	 released	 from	
oxyntic	 cells	 of	 the	 stomach	mucosa.	The	 ability	 of	
ghrelin	to	stimulate	growth	hormone	(GH)	release	by	
activating	GH	secretagogue	 receptors	 (GHSRs	1a)	 in	
the	pituitary	was	discovered	[22].	Ghrelin	has	several	
other	 peripheral	 actions,	 including	 direct	 effects	 on	
the	 systemic	 vascular	 resistance,	 gastric	 secretion,	
stomach	motility,	sleep,	learning,	and	memory	[23-27].	
Additionally,	 recent	 studies	 highlighted	 that	 ghrelin	
also	exerts	neuroprotective	actions	in	ischemic	models	
of	stroke	both	in vivo and in vitro [28,	29].
Therefore,	 our	 study	was	 conducted	 to	 search	 the	
effects	 of	 ghrelin	 on	 TGCI-induced	 hippocampal	
damage	 and	 memory	 impairments	 together	 with	 its	
relation	to	apoptotic,	oxidant,	and	NO/NOS	signaling	
in	rats.
METHODS
Animals. Forty-five	 adult	male	Wistar	 rats	weighing	
300-350	g	were	used	for	the	experiments.	The	animals	
were	housed	at	room	temperature	(23	±	1°C)	and	12-h	
day/night	cycle	and	supplied	with	standard	laboratory	
chow	and	water	ad libitum.	
Experimental Procedures. Rats	 were	 randomly	
divided	 into	 control	 (C),	 ischemia/reperfusion	 (IR)	
and	 ischemia/reperfusion+ghrelin	 (IR+G)	 groups	 (n 
=	15	 in	each	group).	Rats	of	 the	C	group	underwent	
sham	 surgery,	 i.e.,	 without	 vessel	 occlusion,	 and	
received	 saline	 via	 intraperitoneal	 (i.p.)	 daily	
injections	of	vehicle	after	 reperfusion	for	 three	days.	
The	 IR-group	 rats	 were	 exposed	 to	 global	 cerebral	
ischemia/reperfusion	and	received	daily	saline	via	i.p.	
injections	of	vehicle	also	for	three	days	of	reperfusion.	
Rats	 of	 the	 IR+G	 group,	 underwent	 global	 cerebral	
ischemia/reperfusion	 surgery	 and	 received	 daily	
ghrelin	 injections	 (80	 µg/kg·day,	 i.p.)	 as	 treatment	
for	 three	 post-reperfusion	 days	 [28].	 The	 Y-maze	
and	open	field	 tests	were	carried	out	on	 the	 first	and	
second	 post-reperfusion	 days.	 The	Y-maze	 test	 was	
followed	by	 the	open	 field	 test	with	a	1-h-long	 time	
interval.	On	the	third	day	after	reperfusion,	rats	were	
perfused	 transcardially	with	heparinized	saline	under	
deep	 urethane	 anesthesia;	 the	 brains	 were	 removed	
immediately,	and	the	extracted	hippocampi	were	stored	
at	–80°C	for	biochemical	assays.
Drug Preparation. Rat	 ghrelin,	 purchased	 from	
GenScript	 Inc.	 (USA)	 was	 dissolved	 in	 distilled	
water	 (1	mg/ml),	 and	 stored	 at	 –20°C	until	 the	 time	
of	preparation	for	administration.	Immediately	before	
administration	 by	 i.p.	 injection,	 ghrelin	was	 diluted	
again	with	 0.9%	 saline	 to	 the	 final	 concentration	 of	
0.1	mg/ml.	[30].
Global Cerebral Ischemia/Reperfusion. Global	
ischemia	 was	 induced	 by	 four-vessel	 occlusion	 
(4-VO),	 as	 previously	 described	 by	 Pulsinelli	 and	
Brierley	 [31],	 with	 a	 modification.	 In	 brief	 [32],	
an	 incision	was	made	 2.5	 cm	 dorsal	 to	 the	 cervical	
midline	 under	 deep	 ketamine/xylazine	 anesthesia	 
(100/10	 mg/kg,	 i.p.),	 and	 vertebral	 arteries	 were	
irreversibly	 occluded	 by	 electrocoagulation	 through	
the	 alar	 foraminae	 of	 the	 1st	 cervical	 vertebra.	
Immediately	 after	 electrocoagulation,	 bitemporal	
subdermal	 EEG	 needle	 electrodes	 were	 placed	 in	
reference	 to	 a	 frontal	 subdermal	 electrode,	 and	 an	
incision	was	made	2.5	cm	with	 respect	 to	 the	ventral	
cervical	 midline.	 After	 a	 baseline	 EEG	 level	 had	
been	 estimated,	 both	 common	 carotid	 arteries	 were	
exposed	 and	 occluded	 with	 micro	 aneurysm	 clips	
for	 8	 min,	 and	 this	 was	 followed	 by	 reperfusion.	
The	experiments	were	performed	only	 if	 the	animals	
showed	 a	 completely	 flat	 bitemporal	 EEG	 during	
the	 carotid	 artery	 occlusion.	 Sham-operated	 rats	
underwent	 all	 procedures	 except	 the	 latter	 bilateral	
common	carotid	artery	occlusion.	A	heating	pad	was	
applied	in	order	to	maintain	the	rats’	body	temperature	
at	 37	 ±	 0.5°C.	 Each	 group	 of	 animals	 received	 the	
same	degree	of	 surgical	manipulations	and	 the	 same	
recovery	paradigms,	to	minimize	variations	that	could	
be	induced	by	surgical	procedures.	
Behavioral Tests 
The Y-maze Test. Spatial	memory	was	 evaluated	
using	a	Y-maze	test	paradigm	[33]	at	24	and	48	h	after	
ischemia.	The	maze	was	constructed	of	grey	Plexiglas	
and	 consisted	 a	 stem	 arm	 (42	 cm	 long)	 and	 two	
identical	arms	 (37	cm	 long,	diverging	at	a	45°	angle	
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from	the	stem	arm)	surrounded	by	extra-maze	cues	of	
varying	shapes	and	sizes.	During	15-min	information	
trial,	 rats	were	 free	 to	explore	 the	stem	arm	and	one	
of	the	second	arms,	but	access	to	the	third	arm	(novel	
arm)	was	blocked	by	a	plastic	partition.	Following	the	
initial	 information	 trial,	 rats	 were	 returned	 to	 their	
home	 cages	 for	 a	 4-h-long	 interval.	After	 the	 delay,	
each	 rat	 re-entered	 the	Y-maze	 in	 the	 stem	 arm	 and	
was	allowed	to	explore	all	 three	arms	during	a	5-min	
retention	 trial.	Retention	 trials	were	 video-recorded	
(Noldus	Ethovision	XT	System,	country?)	for	scoring	
the	 arm	 entries.	Arm	 entry	 was	 defined	 as	 all	 four	
paws	crossed	 the	dividing	 line	between	 the	 arm	and	
the	 central	 area.	 The	maze	 was	 cleaned	 thoroughly	
with	 70%	 ethanol	 and	 air-dried	 after	 each	 trial	 to	
remove	olfactory	cues.	Spatial	memory	was	indicated	
by	 increased	 entries	 into	 the	 novel	 arm	 during	 the	
retention	trial.
Open Field. Exploratory	 behavior	 was	 tested	
in	 an	 open	 field	 constructed	 of	 black	 Plexiglas	 
(100	cm	×	100	cm	×	45	cm)	arena.	Each	rat	was	placed	
in	 the	 center	 of	 the	 open	 field	 and	 allowed	 a	 single	
exploration	 trial	 of	3	min.	The	 floor	 and	walls	were	
cleaned	 thoroughly	with	70%	ethanol	and	allowed	 to	
air-dry	after	each	trial,	to	remove	olfactory	cues.	The	
activity	was	monitored	by	a	video	camera	and	recorded	
to	 allow	 for	 later	 analysis.	 The	 field	 was	 virtually	
divided	 into	 16	 equal-sized	 squares.	 Entry	 into	 a	
square	was	scored	when	the	rat	crossed	the	borders	of	
a	 designated	 square	with	 all	 four	 paws.	Exploratory	
behavior	 and	 locomotor	 activity	 were	 evaluated	 by	
calculating	 the	 total	 number	 of	 squares	 entered	 and	
total	distance	moved,	respectively	[33].
Biochemical Assays
Estimation of the Total Oxidant Status (TOS). 
Total	oxidant	status	was	measured	by	a	commercially	
available	TOS	assay	kit	(cat.	No.	RL0024,	Rel	Assay	
Diagnostics,	Turkey). The	assay	was	calibrated	with	
hydrogen	 peroxide,	 and	 the	 results	 are	 expressed	
below	as	µM	H
2
O
2
/g	protein.
NO Metabo l i t e s  (N i tr i t e+Ni tra te ) .  The	
nitrite+nitrate	level	was	measured	using	a	commercial	
nitrate/nitrite	colorimetric	assay	kit	 (cat.	No.	78001;	
Cayman	 Chemical,	 USA)	 in	 accordance	 with	 the	
manufacturer’s	 instructions.	Briefly,	 the	hippocampi	
were	 dissected	 on	 ice,	 homogenized	 in	 PBS,	 and	
centrifuged	 at	 10,000g	 for	 20	min.	The	 supernatant	
was	 centrifuged	 at	 100,000g	 for	 30	 min	 and	 then	
filtered	through	a	10-kDa	molecular	mass	cutoff	filter.	
The	nitrate+nitrite	level	was	measured	in	duplicate	on	
96-well	plastic	microplates.	The	absorbance	was	read	
at	570/620	nm	using	a	multiwell	microplate	reader.
Immunohistochemistry of iNOS, nNOS, and 
Caspase-3. Under	 deep	 anesthesia,	 animals	 were	
perfused	transcardially	with	200	ml	of	saline	followed	
by	300	ml	of	4%	paraformaldehyde	solution.	Brains	were	
removed	and	postfixed	 in	 the	same	paraformaldehyde	
solution	for	24	h	and	then	embedded	in	paraffin.	Five-
μm-thick	coronal	sections	were	cut,	collected	on	poly-
L-lysine	 coated	 slides	 (Sigma–Aldrich,	 USA)	 and	
incubated	overnight	at	56°C.	For	immunohistochemical	
assays,	brain	sections	were	deparaffinized	in	xylene	and	
rehydrated	 in	 a	 graded	 ethanol	 series.	 Sections	were	
then	 treated	with	10	mM	citrate	buffer	 (pH	6.0)	 for	5	
min	 twice	 in	a	microwave	oven	and	 left	 to	cool	down	
for	20	min.	After	 three	washes	 in	phosphate-buffered	
saline	 (PBS),	 sections	were	 incubated	 in	 a	 universal	
blocking	reagent	(BioGenex,	USA)	for	7	min	at	 room	
temperature	 in	 order	 to	 block	 nonspecific	 binding.	
Subsequently,	 sections	 were	 incubated	 overnight	 at	
4	 °C	 with	 rabbit	 anti-iNOS	 (1:200;	 ab3523),	 rabbit	
anti-nNOS	(1:100;	ab76067,	both	from	Abcam,	USA)	
and	 cleaved	 caspase-3	 (1:100,	 Cell	 Signaling	 No.	
9661)	 primary	 antibodies.	 After	 several	 washes	 in	
PBS,	 sections	 were	 incubated	 with	 goat	 anti-rabbit-
biotin	secondary	antibody	(1:400;	Vector	Labs,	USA)	
for	60	min	at	 room	temperature	and	rinsed	with	PBS.	
Visualization	 was	 performed	 via	 a	 streptavidin-
peroxidase	complex	(Dako,	USA)	and	diaminobenzidine	
(BioGenex).	Sections	were	counterstained	with	Mayer’s	
hematoxylin	 (Dako),	mounted	with	Kaisers	Glycerol-
Gelatin	 (Merck	 Kaisers	 Glycerin	 Gelatine,	 Cat	 No:	
1.09242.0100,	,	Germany),	and	were	examined	using	a	
light	microscope.
Statistical Analysis. The	obtained	numerical	data	
were	treated	by	SPSS	(version	18.0)	software	package	
for	Windows.	Since	the	numbers	of	entries	to	the	novel	
arm	in	the	Y-maze	did	not	follow	a	normal	distribution,	
and	 their	 variance	 did	 not	 fit	 the	 assumption	 of	
homoscedasticity,	 the	 relevant	 data	 are	 expressed	
as	 medians	 (min-max),	 while	 the	 remaining	 results	
are	 expressed	 as	means	 ±	 s.e.m.	All	 variables	 were	
analyzed	with	the	non-parametric	Kruskal-Wallis	test,	
and	all	pairwise	multiple	comparisons	were	performed	
by	the	Mann-Whitney	U	test;	differences	with	P values 
smaller	than	0.05	were	considered	significant.
RESULTS
TGCI-Induced Spatial Memory Changes and 
Effects of Ghrelin Treatment. Table	1	shows	number	
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of	 entries	 to	 the	 novel	 arm	 and	 total	 distance	moved	
in	the	Y-maze.	The	number	of	entries	to	the	novel	arm	
and	total	distance	moved	were	smaller	in	the	IR	group	
with	 respect	 to	 the	C	group	on	both	post-reperfusion	
day	 1	 and	 day	 2.	 On	 day	 1,	 ghrelin	 administration	
resulted	in	an	increase	of	the	number	of	entries	to	the	
novel	arm,	as	compared	to	the	IR	group;	however,	on	
day	2	no	significant	effect	of	 the	drug	was	observed.	
Ghrelin	treatment	did	not	cause	significant	changes	in	
the	total	distance	moved	in	the	IR+G	group	neither	on	
day	1	nor	on	day	2.
TGCI-Induced Motor Activity Changes and 
Effects of Ghrelin Treatment. The	number	of	squares	
entered and total distance moved in the	open	field	test	
F i g. 1. Total	oxidant	status	(µmol	H
2
O
2
/g	protein)	 in	 the	hippo-
campi	of	rats	of	the	C	(n	=	12),	IR	(n	=	6),	and	IR+G	(n	=	5)	groups.	
Means	 ±	 s.e.m.	 are	 shown;	 *	 indicates	 a	 significant	 difference	 
(P <	0.05)	with	respect	to	group	C.
Р и с. 1.	 Загальний	 оксидантний	 статус	 (мкмоль	 H
2
O
2
/г	
протеїну)	в	гіпокампах	щурів	груп	контролю	(C,	n	=	12),	ішемії-
реперфузії	(IR,	n	=	6)	та	ішемії-реперфузії+грелін	(IR+G,	n	=	5).	
F i g. 2.	Nitrite+nitrate	 levels	(µmol/g	protein)	 in	 the	hippocampi	
of	the	C,	IR,	and	IR+G	groups.	Designations	are	similar	to	those	in	
Fig.	1.
Р и с. 2.	Рівні	нітритів+нітратів	(мкмоль/г	протеїну)	в	гіпо	кам-
пах	щурів	груп	C,	IR	та	IR+G.
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T a b l e 1. Indices observed in the Y-maze test.
Т а б л и ц я 1. Результати тестування у Y-подібному лабіринті.
Groups Number	of	entries	to	the	novel	arm Total	distance	moved	(cm)
Day1 Day	2 Day1	 Day	2
C	(n	=	15) 2.00	±	(0.00-8.00) 1.50	±	(0.00-4.00) 717.6	±	46.2 744.2	±	55.0
IR	(n =	9) 0.00	±	(0.00-1.00)* 0.00	±	(0.00-2.00)* 467.6	±	39.9* 367.3	±	67.8*
IR+G	(n	=	8) 1.00	±	(0.00-2.00)+ 0.00	±	(0.00-6.00) 378.1	±	33.6* 396.3	±	24.8*
Footnotes.	Numbers	of	entries	to	the	novel	arm	are	expressed	as	medians	±	(min-max),	while	other	results	are	expressed	as	means	±	s.e.m.	 
*P	<	0.05	compared	to	the	C	group,	+P	<	0.05	compared	to	the	IR	group.
T a b l e 2. Indices observed in the open field test.
Т а б л и ц я 2. Результати тестування у відкритому полі.
Groups Number	of	squares	entered Total	distance	moved	(cm)
Day	1	 Day	2 Day1	 Day	2
C	(n	=	15) 28.79	±	4.01 27.67	±	3.73 679.8	±	90.2 691.8	±	101.0
IR	(n	=	9) 8.67	±	1.04* 8.83	±	1.56* 386.2	±	38.6* 436.5	±	63.3*
IR+G	(n	=	8) 19.00	±	4.16+ 22.33	±	4.04+ 515.9	±	75.6+ 612.1	±	74.1+
Footnotes.	Means	±	s.e.m	are	shown,	*P <	0.05	compared	to	the	C	group,	+ P	<	0.05	compared	to	the	IR	group.
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A
B
C
B
C
A
F i g. 3. iNOS	expression	in	hippocampal	slices	of	rats	of	the	C,	IR,	
and	IR+G	groups	(A-C,	respectively);	40x.
Р и с. 3.	Експресія	iNOS	у	зрізах	гіпокампа	щурів	груп	C,	IR	та	
IR+G	(A-C	відповідно).
F i g. 4. nNOS	expression	in	hippocampal	slices	of	rats	of	the	C,	IR,	
and	IR+G	groups	(A-C,	respectively);	40x.
Р и с. 4.	Експресія	nNOS	у	зрізах	гіпокампа	щурів	груп	C,	IR	та	
IR+G	(A-C	відповідно).
for	all	experimental	groups	are	shown	in	Table	2.	Both	
these	indices	were	significantly	lower	in	the	IR	group	
compared	 to	 the	 C	 group	 on	 both	 day	 1	 and	 day	 2.	
Ghrelin	 administration	 significantly	 increased	 both	
the	number	of	 squares	entered	and	 the	 total	distance	
moved	 on	 day	 1	 and	 day	 2	 in	 the	 IR+G	 group	with	
respect	to	the	IR	group.	
Hippocampal TOS Levels. Total	 oxidant	 status	
results	are	illustrated	by	Fig.	1.	The	respective	index	was	
significantly	greater	in	the	IR	group	(18.41	±	1.14	µM	 
H
2
O
2
/g	protein)	 in	 reference	 to	 the	C	group	 (12.19	±	
±	0.67	µM	H
2
O
2
/g	protein).	Ghrelin	treatment	lowered	
the	TOS	 level	 in	 the	 IR+G	group	 (16.19	±	 2.16	µM	
H
2
O
2
/g	protein)	with	respect	to	the	IR	group;	however,	
this	effect	was	not	statistically	significant.
Hippocampal Nitrite+Nitrate Levels. Nitrite and 
nitrate	 levels	 in	 the	 hippocampus	 are	 shown	 in	 Fig.	
2.	These	 levels	were	 higher	 in	 both	 the	 IR	 (33.61	±	 
±	4.59	µM/g	protein)	and	IR+G	groups	(25.05	±	3.16	
µM/g	 protein)	 than	 in	 C	 group	 (18.17	 ±	 0.92	 µM/g	
protein).	 Although	 a	 decrease	 in	 the	 hippocampal	
nitrite+nitrate	levels	was	observed	in	the	IR+G	group	
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compared	to	the	IR	group,	the	difference	did	not	rich	
the	level	of	significance.
Hippocampal iNOS Expression. Hippocampal 
iNOS	 immunoreactivity	 (brown	 straining)	 was	
evaluated	 by	 immunohistochemistry	 (Fig.	 3).	 The	
immunoreactivity	 with	 respect	 to	 iNOS	 in	 the	
hippocampus	was	significantly	higher	in	the	IR	group	
(Fig.	 3B)	 with	 respect	 to	 the	 C	 group	 (Fig.	 3A).	
Ghrelin	treatment	noticeably	decreased	the	number	of	
iNOS-positive	neurons	in	the	IR+G	group	(Fig.	3C)	in	
reference	to	the	IR	group.
Hippocampal nNOS expression. Hippocampal 
nNOS	 immunoreactivity	 (brown	 staining)	 was	 also	
evaluated	 by	 immunohistochemistry	 (Fig.	 4).	 The	
nNOS	 immunostaining	 was	 mostly	 observed	 in	 the	
hippocampi	in	the	IR	group	(Fig.	4B).	There	was	weak	
nNOS	 immunolabelling	 found	 in	 the	 IR+G	 group	 
(Fig.	 4C).	 No	 significant	 difference	 was	 observed	
between	 the	 nNOS	 immunoreactivity	 in	 the	 C	 and	
IR+G	groups.
Hippocampal Cleaved Caspase-3 Expression. 
Immunohistochemical	 analysis	 of	 the	 hippocampal	
region	 demonstrated	 that	 the	 caspase-3	 level	 was	
elevated	after	TGCI	in	the	IR	group	(Fig.	5B).	Ghrelin	
caused	 a	 strong	 decrease	 in	 the	 caspase-3	 level	 in	
the	 IR+G	 group	 (Fig.	 5C)	 compared	 to	 the	 above-
mentioned	 IR	 group.	 No	 caspase-3	 expression	 was	
observed	in	the	C	group	(Fig.	5A).	
DISCUSSION
Even	 though	 TGCI	 is	 one	 of	 the	 leading	 causes	 of	
human	 death	 and	 disability	 across	 the	 world	 [34],	
there	 are	 still	 very	 limited	 therapeutic	 options	 [35].	
Hence,	 this	 dramatic	 disorder	 remains	 a	 demanding	
clinical	 problem	 for	 which	 the	 development	 of	 new	
therapies	is	necessary.	
Patients	 who	 experienced	 TGCI	 usually	 suffer	
from	 various	 degrees	 of	 memory	 impairment	 and	
learning	 dysfunction	 due,	 to	 a	 significant	 extent,	 to	
the	hippocampal	damage	[36,	37].	Circulating	ghrelin	
in	 the	 hippocampus	 was	 shown	 to	 cross	 the	 blood-
brain	 barrier,	 to	 enhance	 long-term	 potentiation	
(LTP),	and	to	improve	spatial	memory	[38].	Based	on	
these	results,	we	investigated	the	possible	therapeutic	
effects	 of	 ghrelin	 on	 TGCI-induced	 deterioration	
of	 spatial	memory	 and	 exploratory	 behavior	 in	 rats.	
Our	 data	 suggested	 that	 ghrelin	 has	 a	 clear	 positive	
effect	 on	 spatial	 memory	 impairment	 induced	 by	
TGCI	on	 the	first	day	after	 reperfusion.	However,	 its	
protective	effect	mostly	vanished	on	the	second	post-
reperfusion	day.	This	situation	might	occur	due	to	an	
insufficient	dose	of	ghrelin	used	 in	our	experiments.	
In	 other	words,	 as	 hippocampus-dependent	memory	
impairment	 progresses	 within	 the	 reperfusion	
period,	an	administered	amount	of	ghrelin	could	not	
be	 adequate	 to	 overcome	 the	 damage	 within	 later	
segments	of	 the	post-reperfusion	period.	 In	addition,	
ghrelin	 administration	 resulted	 in	 enhancement	 of	
motor	 activity	 that	 was	 previously	 deteriorated	 by	
TGCI.	 The	 alleviative	 effect	 of	 ghrelin	 on	 motor	
activity	was	 observed	 not	 only	 on	 the	 first	 day,	 but	
B
C
A
F i g. 5. Caspase-3	expression	in	hippocampal	slices	of	rats	of	the	
C,	IR,	and	IR+G	groups	(A-C,	respectively);	40x.
Р и с. 5.	Експресія	каспази-3	у	зрізах	гіпокампа	щурів	груп	C,	
IR	та	IR+G	(A-C	відповідно).
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also	 on	 the	 second	 day	 after	 reperfusion.	Although	
memory-	 and	 motor	 activity-enhancing	 effects	 of	
ghrelin	were	reported	in	the	literature,	the	underlying	
mechanism	 has	 not	 been	 fully	 understood	 yet	 [39].	
Therefore,	 further	 studies	 are	 required	 to	 clarify	 the	
mechanisms	of	action	of	this	agent.
The	 hippocampus	 is	 selectively	 vulnerable	 to	
TGCI;	 hippocampal	 degeneration	 begins	 to	 be	
observed	 histologically	 2-3	 days	 after	 ischemia	 [6].	
In	 reference	 to	 these	 crucial	 findings,	we	 evaluated	
apoptotic	 changes	 in	 the	 hippocampus	 three	 days	
after	ischemia	via	caspase-3	immunostaining,	in	order	
to	 see	 is	 there	 any	 correlation	 between	 behavioral	
and	 apoptotic	 changes.	Ultimately,	 higher	 caspase-3	
immunoreactivity	was	observed	 in	 the	 IR	group	with	
respect	 to	 the	 C	 group.	 In	 the	 same	 line	 with	 our	
findings,	Liu	et	al.	[40]	showed	that	8-min-long	TGCI	
resulted	 in	 dramatic	 cell	 loss	 in	 the	 hippocampus	
three	days	after	ischemia.	Pooling	our	behavioral	and	
histological	results	together,	we	can	suggest	that	TGCI	
causes memory impairment by inducing DND via an 
apoptotic	pathway	in	the	hippocampus.	
At	 present,	 a	 few	 investigations	 are	 being	 carried	
out	 in	 order	 to	 suggest	 neuroprotective	 therapies	 to	
overcome	hippocampal	degeneration	caused	by	TGCI.	
Recent	 studies	 highlighted	 neuroprotective	 actions	
of	ghrelin	 in	 ischemic	models	of	stroke,	both	 in vivo 
and in vitro.	In vivo rat	IR	models	showed	that	ghrelin	
provides	 significant	neuroprotection	 in	 the	 forebrain	
by	reducing	an	infarct	volume	and	cell	death	[28,	29].	
We	 also	 observed	 that	 ghrelin	 treatment	 (80	 µg/kg)	 
lowered	 the	caspase-3	 immunoreactivity	 in	 the	 IR+G	
group.	 Together	 with	 behavioral	 changes,	 it	 might	
be	 suggested	 that	 ghrelin	 attenuates	 TGCI-induced	
memory	impairment	by	affecting	an	apoptotic	pathway.	
In	 that	 respect,	 ghrelin	 might	 be	 considered	 as	 a	
potential	therapeutic	mean	with	respect	to	hippocampal	
TGCI	 injury.	Therefore,	 further	 researches	should	be	
conducted	in	order	to	find	out	the	details	of	molecular	
pathway	mediating	the	anti-apoptotic	action	of	ghrelin.	
Oxidative	 stress,	 the	 consequence	 of	 free	 radical	
overproduction,	is	a	well-identified	pathophysiological	
mechanism	of	 IR	 injury	 [41,	42].	With	 the	beginning	
of	reperfusion,	abrupt	oxygenation	of	the	brain	tissue	
causes	 excessive	 production	 of	 oxygen	 radicals	
intensely	 oxidizing	 membrane	 lipids, 	 cellular	
proteins,	 and	 DNA,	 thus	 leading	 to	 intensification	
of	 apoptosis	 [43].	 In	 our	 study,	 similar	 to	 previous	
reports,	we	also	observed	an	elevation	of	TOS	 in	 the	
hippocampus	 after	 TGCI.	We,	 however,	 found	 that	
ghrelin	administration	did	not	significantly	 lower	 the	
TOS	level	in	the	IR+G	group.	At	the	same	time,	other	
authors	 [44,	 45]	 suggested	 that	 ghrelin	 expression	
affects	 oxidative	 stress	 in	 different	 cell	 types.	 Our	
negative	 result	might	be	 related	 to	a	dose	of	ghrelin	
insufficient	 to	 reduce	 oxidative	 stress	 significantly.	
In	 order	 to	 clarify	 the	 pathways	mediating	 possible	
effects	of	ghrelin,	protein	 levels,	mRNA	expression,	
and	activities	of	both	oxidant	and	antioxidant	enzymes	
should	be	investigated	in	a	dose-dependent	manner	in	
further	studies.
Nitric	oxide,	 a	highly	 reactive	 signaling	molecule	
in	 the	 CNS	 is	 one	 of	 the	 free	 radicals	 elevated	
during	 ischemic	 brain	 injury	 [46].	 Being	 a	 gaseous	
chemical	messenger,	NO	plays	 key	 roles	 in	 neuron-
to-neuron	 communication,	 synaptic	 plasticity,	 and	
memory	 formation	 [47,	 48].	 Unless	 existing	 in	
physiological	 low	 concentrations,	 NO	 might	 affect	
the	 tissues	 through	 toxic	actions	mediated	mostly	by	
the	peroxinitrite	 radical	 (ONOO-)	 [49].	Although	not	
being	fully	understood	yet,	the	mechanism	underlying	
TGCI	injury	is	suggested	to	involve	NO	signaling	due	
to	the	induction	of	excessive	NO	production	[50,	51].	
Together	with	NO,	the	levels	of	its	metabolites,	such	as	
nitrites	and	nitrates,	are	also	elevated	following	TGCI	
[52].	 In	 our	 study,	 a	marker	 of	 NO	 production,	 the	
nitrite+nitrate	level,	was	elevated	in	the	hippocampus	
after	TGCI.	We	observed	 that	ghrelin	administration	
lowered	 this	 level	 in	 the	 hippocampi	 in	 the	 IR+G	
group,	but	 the	effect	was	not	statistically	significant.	
Alterations	 in	 the	nitrite+nitrate	concentration	might	
be	 explained	 by	 changes	 in	 the	 hippocampal	 NOS	
levels.
Nitric	 oxide	 is	 a	 “double-edged	 sword”	 in	 IR	
injury;	 in	 addition	 to	 the	 amount,	 the	 source	 of	NO	
is	 another	 crucial	 factor	 dominating	 its	 effects	 in	
cerebral	 ischemia.	 Nitric	 oxide	 produced	 by	 eNOS	
has	been	suggested	 to	exert	beneficial	effects	during	
cerebral	 ischemia-reperfusion;	nNOS	and,	especially,	
iNOS	 are	 considered	 to	 be	 detrimental	 since	 they	
produce	 a	 considerable	 amount	 of	 NO	 resulting	 in	
DNA	 damage	 [53].	We	 found	 that	 iNOS	 and	 nNOS	
immunoreactivities	were	 raised	 in	 the	 hippocampus	
after	TGCI.	Therefore,	 the	 high	 nitrite+nitrate	 level	
in	 the	 IR	group	can	be	attributed	 to	 increases	 in	 the	
iNOS	and	nNOS	levels.	The	 latter	effect	 (increase	of	
iNOS	and	nNOS	expressions)	was	 reported	by	other	
authors	in	focal	cerebral	ischemia	models	in	mice	and	
rats	 [54-56].	 Ghrelin	 treatment,	 on	 the	 other	 hand,	
lowered	 iNOS	 and	 nNOS	 immunoreactivities	 in	 the	
IR+G	group,	as	compared	with	 the	 IR	group.	Hence,	
we	 can	 conclude	 that	 the	 lower	 nitrite+nitrate	 level	
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was	 a	 consequence	of	 decreases	 in	 iNOS	and	nNOS	
expressions	 in	 the	 IR+G	 group	 with	 respect	 to	 the	
IR	group.	 Indeed,	ghrelin	has	 in	several	 reports	been	
suggested	 to	modulate	 NO/NOS	 signaling	 [57,	 58].	
Brzozowski	 et	 al.	 [58]	 showed	 that	 ghrelin	 inhibits	
expression	 of	 iNOS	mRNA	 under	 stress	 conditions	
and	upregulates	constitutive	NOS	(eNOS	and	nNOS)	
mRNA.	Additionally,	Carlini	et	al.	[57]	suggested	that	
ghrelin	affects	memory	consolidation	and	reduces	the	
LTP	threshold	through	the	NO/NOS	signaling	pathway.	
Similarly	 to	previous	 studies,	 the	observed	effect	of	
ghrelin	 on	 TGCI-induced	 memory	 changes	 in	 our	
study	might	also	to	a	noticeable	extent	be	attributed	to	
NO/NOS	pathway	modulation.
Thus,	we	examined	the	effects	of	ghrelin	on	TGCI-
induced	 behavioral	 impairment	 and	 accompanying	
changes	 in	 the	 apoptotic,	 oxidant,	 and	 NO/NOS	
pathways	 in	 the	 rat	hippocampus.	Pooling	all	 results	
together,	 ghrelin	 might	 be	 a	 candidate	 drug	 for	
treatment	 of	 TGCI-induced	 memory	 impairment	
provided	 that	 the	 underlying	mechanisms	 should	 be	
fully	clarified	in	further	studies.
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Р	е	з	ю	м	е
У	наших	дослідах	ми	вивчали	зміни	просторової	пам’яті	та	
моторної	активності,	викликані	в	щурів	транзієнтною	гло-
бальною	 церебральною	 ішемією	 (ТГЦІ).	 Використовува-
ли	тести	в	Y-подібному	лабіринті	та	відкритому	полі;	оці-
нювали	також	параметри	процесу	апоптозу,	оксидативного	
стресу	та	сигнального	шляху	оксиду	азоту.	Розлади	просто-
рової	пам’яті	та	моторної	активності	під	впливом	греліну	
(ендогенного	ліганда	рецепторів	гормону	росту)	зменшува-
лися.	Крім	того,	в	результаті	введень	греліну	знижувалися	
рівні	каспази-3	та	 індуцибельної	NO-синтази	в	гіпокампі,	
що	були	підвищеними	після	ТГЦІ.	Зроблено	висновок,	що	
грелін	має	нейропротективні	властивості	в	умовах	ушкод-
ження	 гіпокампа	 в	 наслідок	 ТГЦІ,	 впливаючи	 на	 процес	
апоптозу,	 оксидативний	 стрес	 та	 стан	 сигнального	шляху	
оксиду	азоту.	Якщо	механізми	дії	цього	агента	будуть	до-
кладно	 з’ясовані,	 грелін	 може	 виявитися	 перспективним	
фармакологічним	засобом	при	лікуванні	розладів	пам’яті,	
пов’язаних	з	ТГЦІ.	
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